Australia is gain access to potentially transformative medication for weight issues: Retatrutide. This dual agonist – acting on both GLP-1 and GIP receptors – shows remarkable results in global studies, pointing to substantial drops in BMI. While regulatory clearance remains with Australian regulators, many individuals battling being overweight